Shots:

• The P-III study evaluates the efficacy and safety of TX05 vs Herceptin (trastuzumab) in patients with human epidermal growth factor receptor 2-positive early breast cancer
• The 1EPs was an assessment of pCR following neoadjuvant therapy and definitive surgery in the per-protocol population
• Results: Patients achieved pCR (48.8% vs 45.3%) in the per-protocol population

 ­ Ref: Tanvex  | Image: Tanvex